Copyright Reports & Markets. All rights reserved.

Global and Japan Wet Age Related Macular Degeneration (AMD) Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Wet Age Related Macular Degeneration (AMD) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Wet Age-Related Macular Degeneration (Wet AMD)
    • 1.2.3 Dry Age-Related Macular Degeneration (Dry AMD)
  • 1.3 Market by Application
    • 1.3.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Application: 2020 VS 2026
    • 1.3.2 Above 75 Years
    • 1.3.3 Above 60 Years
    • 1.3.4 Above 40 Years
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Wet Age Related Macular Degeneration (AMD) Market Perspective (2015-2026)
  • 2.2 Global Wet Age Related Macular Degeneration (AMD) Growth Trends by Regions
    • 2.2.1 Wet Age Related Macular Degeneration (AMD) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Wet Age Related Macular Degeneration (AMD) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Wet Age Related Macular Degeneration (AMD) Players by Market Size
    • 3.1.1 Global Top Wet Age Related Macular Degeneration (AMD) Players by Revenue (2015-2020)
    • 3.1.2 Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Players (2015-2020)
  • 3.2 Global Wet Age Related Macular Degeneration (AMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Wet Age Related Macular Degeneration (AMD) Revenue
  • 3.4 Global Wet Age Related Macular Degeneration (AMD) Market Concentration Ratio
    • 3.4.1 Global Wet Age Related Macular Degeneration (AMD) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Wet Age Related Macular Degeneration (AMD) Revenue in 2019
  • 3.5 Key Players Wet Age Related Macular Degeneration (AMD) Area Served
  • 3.6 Key Players Wet Age Related Macular Degeneration (AMD) Product Solution and Service
  • 3.7 Date of Enter into Wet Age Related Macular Degeneration (AMD) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Wet Age Related Macular Degeneration (AMD) Breakdown Data by Type (2015-2026)

  • 4.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Type (2015-2020)
  • 4.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Type (2021-2026)

5 Wet Age Related Macular Degeneration (AMD) Breakdown Data by Application (2015-2026)

  • 5.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Application (2015-2020)
  • 5.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Wet Age Related Macular Degeneration (AMD) Market Size (2015-2026)
  • 6.2 North America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
  • 6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)
  • 6.4 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Wet Age Related Macular Degeneration (AMD) Market Size (2015-2026)
  • 7.2 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
  • 7.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)
  • 7.4 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Wet Age Related Macular Degeneration (AMD) Market Size (2015-2026)
  • 8.2 China Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
  • 8.3 China Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)
  • 8.4 China Wet Age Related Macular Degeneration (AMD) Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Wet Age Related Macular Degeneration (AMD) Market Size (2015-2026)
  • 9.2 Japan Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
  • 9.3 Japan Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)
  • 9.4 Japan Wet Age Related Macular Degeneration (AMD) Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size (2015-2026)
  • 10.2 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Novartis International (Switzerland)
    • 11.1.1 Novartis International (Switzerland) Company Details
    • 11.1.2 Novartis International (Switzerland) Business Overview
    • 11.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.1.4 Novartis International (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020))
    • 11.1.5 Novartis International (Switzerland) Recent Development
  • 11.2 Bayer (Germany)
    • 11.2.1 Bayer (Germany) Company Details
    • 11.2.2 Bayer (Germany) Business Overview
    • 11.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.2.4 Bayer (Germany) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.2.5 Bayer (Germany) Recent Development
  • 11.3 Acucela (US)
    • 11.3.1 Acucela (US) Company Details
    • 11.3.2 Acucela (US) Business Overview
    • 11.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.3.4 Acucela (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.3.5 Acucela (US) Recent Development
  • 11.4 Neurotech Pharmaceuticals (US)
    • 11.4.1 Neurotech Pharmaceuticals (US) Company Details
    • 11.4.2 Neurotech Pharmaceuticals (US) Business Overview
    • 11.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.4.4 Neurotech Pharmaceuticals (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.4.5 Neurotech Pharmaceuticals (US) Recent Development
  • 11.5 Ophthotech (US)
    • 11.5.1 Ophthotech (US) Company Details
    • 11.5.2 Ophthotech (US) Business Overview
    • 11.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.5.4 Ophthotech (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.5.5 Ophthotech (US) Recent Development
  • 11.6 GlaxoSmithKline (US)
    • 11.6.1 GlaxoSmithKline (US) Company Details
    • 11.6.2 GlaxoSmithKline (US) Business Overview
    • 11.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.6.4 GlaxoSmithKline (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.6.5 GlaxoSmithKline (US) Recent Development
  • 11.7 Alimera Sciences (US)
    • 11.7.1 Alimera Sciences (US) Company Details
    • 11.7.2 Alimera Sciences (US) Business Overview
    • 11.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.7.4 Alimera Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.7.5 Alimera Sciences (US) Recent Development
  • 11.8 StemCell (Canada)
    • 11.8.1 StemCell (Canada) Company Details
    • 11.8.2 StemCell (Canada) Business Overview
    • 11.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.8.4 StemCell (Canada) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.8.5 StemCell (Canada) Recent Development
  • 11.9 F. Hoffmann-La Roche (Switzerland)
    • 11.9.1 F. Hoffmann-La Roche (Switzerland) Company Details
    • 11.9.2 F. Hoffmann-La Roche (Switzerland) Business Overview
    • 11.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.9.4 F. Hoffmann-La Roche (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.9.5 F. Hoffmann-La Roche (Switzerland) Recent Development
  • 11.10 Regeneron Pharmaceutical (US)
    • 11.10.1 Regeneron Pharmaceutical (US) Company Details
    • 11.10.2 Regeneron Pharmaceutical (US) Business Overview
    • 11.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Introduction
    • 11.10.4 Regeneron Pharmaceutical (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 11.10.5 Regeneron Pharmaceutical (US) Recent Development
  • 11.11 Allergan (Ireland)
    • 10.11.1 Allergan (Ireland) Company Details
    • 10.11.2 Allergan (Ireland) Business Overview
    • 10.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Introduction
    • 10.11.4 Allergan (Ireland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 10.11.5 Allergan (Ireland) Recent Development
  • 11.12 Adverum Biotechnologies (US)
    • 10.12.1 Adverum Biotechnologies (US) Company Details
    • 10.12.2 Adverum Biotechnologies (US) Business Overview
    • 10.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Introduction
    • 10.12.4 Adverum Biotechnologies (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 10.12.5 Adverum Biotechnologies (US) Recent Development
  • 11.13 Gilead Sciences (US)
    • 10.13.1 Gilead Sciences (US) Company Details
    • 10.13.2 Gilead Sciences (US) Business Overview
    • 10.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Introduction
    • 10.13.4 Gilead Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2015-2020)
    • 10.13.5 Gilead Sciences (US) Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Wet Age Related Macular Degeneration (AMD) Scope and Market Size
    Wet Age Related Macular Degeneration (AMD) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Wet Age Related Macular Degeneration (AMD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Wet Age-Related Macular Degeneration (Wet AMD)
    Dry Age-Related Macular Degeneration (Dry AMD)

    Market segment by Application, split into
    Above 75 Years
    Above 60 Years
    Above 40 Years

    Based on regional and country-level analysis, the Wet Age Related Macular Degeneration (AMD) market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Wet Age Related Macular Degeneration (AMD) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Novartis International (Switzerland)
    Bayer (Germany)
    Acucela (US)
    Neurotech Pharmaceuticals (US)
    Ophthotech (US)
    GlaxoSmithKline (US)
    Alimera Sciences (US)
    StemCell (Canada)
    F. Hoffmann-La Roche (Switzerland)
    Regeneron Pharmaceutical (US)
    Allergan (Ireland)
    Adverum Biotechnologies (US)
    Gilead Sciences (US)

    Buy now